Literature DB >> 874956

Antiarrhythmics. 2. Synthesis and antiarrhythmic activity of N-(piperidylalkyl)trifluoroethoxybenzamides.

E H Banitt, W R Bronn, W E Coyne, J R Schmid.   

Abstract

Benzamides characterized by one or more 2,2,2-trifluoroethoxy ring substituents and a heterocyclic amide side chain have been prepared and evaluated for oral antiarrhythmic activity in mice. The most potent compounds are derived from 2,5-bis(2,2,2-trifluoroethoxy)benzamide, and, within this group, both tertiary as well as secondary benzamides are active. Considerable variation in the heterocyclic ring is permissible, but antiarrhythmic activity is strongly influenced by the basicity of the amine nitrogen and the nature of the link between heterocycle and amide nitrogen. One of these compounds, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide acetate (flecainide acetate, USAN), was studied extensively in animals and selected for clinical trial as an antiarrhythmic.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874956     DOI: 10.1021/jm00216a016

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Effects of potassium channel and Na+-Ca2+ exchange blockers on the responses of slowly adapting pulmonary stretch receptors to hyperinflation in flecainide-treated rats.

Authors:  S Matsumoto; T Nishikawa; S Yoshida; M Ikeda; T Tanimoto; C Saiki; M Takeda
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 2.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

3.  Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions.

Authors:  K A Muhiddin; P Turner; K Hellestrand; A J Camm
Journal:  Postgrad Med J       Date:  1985-06       Impact factor: 2.401

Review 4.  Targeting ryanodine receptors for anti-arrhythmic therapy.

Authors:  Mark D McCauley; Xander H T Wehrens
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

5.  The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.

Authors:  K A Muhiddin; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

6.  Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man.

Authors:  K J Hellestrand; R S Bexton; A W Nathan; R A Spurrell; A J Camm
Journal:  Br Heart J       Date:  1982-08

7.  The proarrhythmic effects of flecainide.

Authors:  A W Nathan; K J Hellestrand; R S Bexton; R A Spurrell; A J Camm
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 8.  The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis.

Authors:  Jordi Heijman; Vincent Algalarrondo; Niels Voigt; Jonathan Melka; Xander H T Wehrens; Dobromir Dobrev; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2015-12-23       Impact factor: 10.787

Review 9.  Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it.

Authors:  Stanley Nattel; Philip T Sager; Jörg Hüser; Jordi Heijman; Dobromir Dobrev
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 10.787

Review 10.  Mechanisms underlying pathological Ca2+ handling in diseases of the heart.

Authors:  Satadru K Lahiri; Yuriana Aguilar-Sanchez; Xander H T Wehrens
Journal:  Pflugers Arch       Date:  2021-01-05       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.